859MO Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial

859MO Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 34; p. S558
Main Authors: Michel, L., Jimeno, A., Sukari, A., Beck, T., Chiu, J.W.Y., Ahern, E.S., Hilton, J., A. Hollebecque, Zanetta, S., Patel, J., Mekan, S., Wu, T., Dumbrava, E.E.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-10-2023
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2023.09.2005